Knockout Tested Rabbit Recombinant Monoclonal IMP3 antibody. Suitable for IP, WB, ICC/IF and reacts with Human samples. Cited in 3 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
IP | Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Tested | Not recommended | Tested |
Rat | Predicted | Not recommended | Predicted | Not recommended | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/10 - 1/100 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/50 - 1/100 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info - | Notes - |
Select an associated product type
RNA-binding factor that may recruit target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation. Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed:29476152). Binds to the 3'-UTR of CD44 mRNA and stabilizes it, hence promotes cell adhesion and invadopodia formation in cancer cells. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD (PubMed:29476152). Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs.
IMP3, KOC1, VICKZ3, IGF2BP3, Insulin-like growth factor 2 mRNA-binding protein 3, IGF2 mRNA-binding protein 3, IMP-3, IGF-II mRNA-binding protein 3, KH domain-containing protein overexpressed in cancer, VICKZ family member 3, hKOC
Knockout Tested Rabbit Recombinant Monoclonal IMP3 antibody. Suitable for IP, WB, ICC/IF and reacts with Human samples. Cited in 3 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Mouse: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
IMP3 also known as IGF2BP3 is an oncofetal protein belonging to the insulin-like growth factor 2 mRNA-binding protein family. It has a molecular weight of around 65 kDa. IMP3 expresses in various tissues including embryonic tissues and several cancer types. In healthy adults the expression is minimal observed mostly in the testis placenta and some parts of the nervous system. It's significance in development and cancer makes it an important target for research.
IMP3 plays a role in the regulation of mRNA stability localization and translation. It is a part of ribonucleoprotein complexes that facilitate these processes by binding to the 3' untranslated regions of target mRNAs. The protein influences the expression of genes involved in cell growth differentiation and migration. IMP3's ability to modulate mRNA fate contributes to cellular events essential for development and has implications in cancer progression.
The involvement of IMP3 is significant in pathways like the insulin-like growth factor (IGF) signaling pathway and epithelial-mesenchymal transition (EMT). Within these pathways IMP3 modulates the activities of proteins such as IGF2 influencing cell proliferation and survival. Its participation in EMT is essential for processes like metastasis in cancer cells linking it to broader biological processes that govern cell movement and identity change.
High IMP3 expression associates with various cancers including pancreatic and ovarian cancers. It has been connected to the progression and poor prognosis of these cancers. In pancreatic cancer IMP3 can interact with proteins like IGF2 enhancing tumor growth and metastasis. This connection makes IMP3 a potential biomarker for cancer diagnostics and therapeutic targeting.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lanes 1 - 4: Merged signal (red and green). Green - ab177942 observed at 70 kDa. Red - loading control, Anti-GAPDH antibody [mAbcam 9484] - Loading Control ab9484, observed at 37 kDa.
ab177942 was shown to specifically react with IGF2BP3 (IMP3) in wild-type HAP1 cells as signal was lost in IGF2BP3 (IMP3) knockout cells. Wild-type and IGF2BP3 (IMP3) knockout samples were subjected to SDS-PAGE. ab177942 and Anti-GAPDH antibody [mAbcam 9484] - Loading Control ab9484 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1/20,000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-IMP3 antibody [EPR12022] (ab177942)
Predicted band size: 63 kDa
Western blot analysis on immunoprecipitation pellet from 293T cell lysate using ab177942.
All lanes: Immunoprecipitation - Anti-IMP3 antibody [EPR12022] (ab177942)
Predicted band size: 63 kDa
Immunofluorescent analysis of HeLa cells labeling IMP3 with ab177942 at 1/50 dilution (green). DAPI nuclear staining (blue).
All lanes: Western blot - Anti-IMP3 antibody [EPR12022] (ab177942) at 1/1000 dilution
Lane 1: Hela cell lysate at 10 µg
Lane 2: 293T cell lysate at 10 µg
Lane 3: K562 cell lysate at 10 µg
Lane 4: HT-29 cell lysate at 10 µg
Predicted band size: 63 kDa
Observed band size: 69 kDa
Western blot: Anti-IGF2BP3 antibody [EPR12022] (ab177942) staining at 1/2000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in magenta. In Western blot, ab177942 was shown to bind specifically to IGF2BP3. A band was observed at 60-75 kDa in wild-type HCT 116 cell lysates with no signal observed at this size in IGF2BP3 knockout cell line. To generate this image, wild-type and IGF2BP3 knockout HCT 116 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
All lanes: Western blot - Anti-IMP3 antibody [EPR12022] (ab177942) at 1/2000 dilution
Lane 1: Wild-type HCT 116 cell lysate at 20 µg
Lane 2: IGF2BP3 knockout HCT 116 cell lysate at 20 µg
Lane 3: Wild-type HAP1 cell lysate at 20 µg
Lane 4: IGF2BP3 knockout HAP1 cell lysate at 20 µg
All lanes: Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Performed under reducing conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com